The world's first oral GLP-1 analog has landed in Korea. Novonodisk announced on the 3rd that it has obtained an item license from the MFDS for oral GLP-1 analog-based type 2 diabetes treatment Rybelsus (Semaglutide).

Rybelsus is used as a dietary and exercise therapy supplement to improve blood sugar control in adults who do not have sufficient control of type 2 diabetes. It is taken once a day, and there is no need to control the dosage of drugs in patients with renal or hepatic dysfunction or in the elderly. Rybelsus demonstrated its validity and safety in eight global clinical studies PIONEER. In particular, it showed a superior blood glucose drop effect than the SGLT-2 inhibitor-based Empagliflozin